

Alan Jardine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/390528/publications.pdf>

Version: 2024-02-01

48
papers

2,283
citations

304368

22
h-index

243296

44
g-index

48
all docs

48
docs citations

48
times ranked

3755
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019, 393, 407-415.	6.3	512
2	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. <i>Lancet Diabetes and Endocrinology,the</i> , 2016, 4, 829-839.	5.5	234
3	Guidelines for the treatment and management of new-onset diabetes after transplantation1.. <i>Clinical Transplantation</i> , 2005, 19, 291-298.	0.8	228
4	Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus: A Randomized, Multicenter, 24-Month Study. <i>Transplantation</i> , 2011, 92, 410-418.	0.5	121
5	Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 384, 1601-1612.	13.9	106
6	Inflammation in Renal Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1246-1254.	2.2	96
7	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 836-849.	2.6	80
8	Effect of rosuvastatin on outcomes in chronic haemodialysis patients â€” design and rationale of the AURORA study. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2005, 6, 9.	1.5	71
9	Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. <i>Kidney International</i> , 2010, 77, 44-50.	2.6	68
10	Title is missing!. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2001, 8, 63-71.	1.5	59
11	Acute Rejection and Chronic Nephropathy: A Systematic Review of the Literature. <i>Transplantation</i> , 2009, 87, 1330-1339.	0.5	57
12	Inflammation-associated graft loss in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3756-3761.	0.4	53
13	Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: A randomized placeboâ€”controlled study. <i>Arthritis and Rheumatism</i> , 2009, 60, 1060-1064.	6.7	51
14	Renal transplant dysfunctionâ€”importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2282-2289.	0.4	50
15	Long- and short-term outcomes in renal allografts with deceased donors: A large recipient and donor genome-wide association study. <i>American Journal of Transplantation</i> , 2018, 18, 1370-1379.	2.6	47
16	Cerebrovascular Events in Renal Transplant Recipients. <i>Transplantation</i> , 2009, 87, 112-117.	0.5	41
17	Serum Uric Acid Level, Longitudinal Blood Pressure, Renal Function, and Long-Term Mortality in Treated Hypertensive Patients. <i>Hypertension</i> , 2013, 62, 105-111.	1.3	37
18	Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2571-2575.	0.4	35

#	ARTICLE	IF	CITATIONS
19	Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. <i>European Heart Journal</i> , 2007, 28, 3027-3033.	1.0	30
20	Prevention of cardiovascular disease after renal transplantation. <i>Current Opinion in Organ Transplantation</i> , 2012, Publish Ahead of Print, 393-400.	0.8	28
21	Polygenic risk score as a determinant of risk of non-melanoma skin cancer in a European-descent renal transplant cohort. <i>American Journal of Transplantation</i> , 2019, 19, 801-810.	2.6	26
22	Summary of the 5th Edition of the Renal Association Clinical Practice Guidelines (2009â€“2012). <i>Nephron Clinical Practice</i> , 2011, 118, c27-c70.	2.3	23
23	Optimal fluid control can normalize cardiovascular risk markers and limit left ventricular hypertrophy in thrice weekly dialysis patients. <i>Hemodialysis International</i> , 2012, 16, 465-472.	0.4	22
24	Anemia is a predictor of graft loss but not cardiovascular events and allâ€“cause mortality in renal transplant recipients: followâ€“up data from the <scp>ALERT</scp> study. <i>Clinical Transplantation</i> , 2013, 27, E636-43.	0.8	22
25	Diagnosis and treatment of coronary artery disease in patients with chronic kidney disease. <i>Heart</i> , 2008, 94, 1080-1088.	1.2	20
26	Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. <i>Clinical Transplantation</i> , 2009, 23, 914-920.	0.8	19
27	Gender-associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study. <i>Clinical Transplantation</i> , 2006, 20, 374-382.	0.8	17
28	Aortic Stiffness and Diastolic Flow Abnormalities in End-Stage Renal Disease Assessed by Magnetic Resonance Imaging. <i>Nephron Clinical Practice</i> , 2008, 109, c1-c8.	2.3	13
29	The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population. <i>American Journal of Transplantation</i> , 2019, 19, 2262-2273.	2.6	13
30	Impact of Long-Term Therapy With FTY720 or Mycophenolate Mofetil on Cardiac Conduction and Rhythm in Stable Adult Renal Transplant Patients. <i>Transplantation</i> , 2007, 83, 645-648.	0.5	11
31	Open new possibilities in Transplantation Research. <i>Transplantation Research</i> , 2012, 1, 1.	1.5	10
32	Neopterin is associated with cardiovascular events and allâ€“cause mortality in renal transplant patients. <i>Clinical Transplantation</i> , 2014, 28, 111-119.	0.8	10
33	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2020, 76, 109-120.	2.1	10
34	Symmetric Dimethylarginine as Predictor of Graft loss and All-Cause Mortality in Renal Transplant Recipients. <i>Transplantation</i> , 2014, 98, 1219-1225.	0.5	9
35	Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis. <i>Free Radical Research</i> , 2017, 51, 14-23.	1.5	9
36	Graft loss risk in renal transplant recipients with metabolic syndrome: subgroup analyses of the ALERT trial. <i>Journal of Nephrology</i> , 2012, 25, 245-254.	0.9	8

#	ARTICLE	IF	CITATIONS
37	Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients. <i>Atherosclerosis</i> , 2010, 208, 234-239.	0.4	7
38	Cardiovascular disease in renal transplantation: Management by statins. <i>Transplantation Reviews</i> , 2004, 18, 122-128.	1.2	6
39	Increased Osteoprotegerin Predicts Poor Virological Outcome During Anticytomegalovirus Therapy in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2015, 99, 100-105.	0.5	6
40	A comparative study of 5 different antibiotic prophylaxis regimes in 4500 total knee replacements. <i>Journal of Clinical Orthopaedics and Trauma</i> , 2020, 11, 108-112.	0.6	6
41	Functional Cardiopulmonary Exercise Testing in Potential Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 8-9.	3.0	5
42	Genetic markers associated with long-term cardiovascular outcome in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 1444-1451.	2.6	4
43	Targeted-release budesonide therapy for IgA nephropathy – Authors' reply. <i>Lancet</i> , The, 2017, 390, 2625-2626.	6.3	2
44	An analysis of vascular access thrombosis events from the Proactive IV Iron Therapy in Hemodialysis Patients (PIVOTAL) trial. <i>Kidney International Reports</i> , 2022, , .	0.4	1
45	Cardiovascular complications of chronic renal disease. <i>Medicine</i> , 2011, 39, 421-424.	0.2	0
46	Do patients with CKD benefit from lipid-lowering therapy?. <i>Nature Reviews Nephrology</i> , 2012, 8, 684-685.	4.1	0
47	FP802 EFFECT OF ALLOPURINOL ON LEFT VENTRICULAR MASS INDEX IN HAEMODIALYSIS PATIENTS - A RANDOMISED CONTROLLED TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i633-i633.	0.4	0
48	Chronic Allograft Nephropathy. , 0, , 599-607.		0